Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Tax Provisions (2016 - 2019)

Aptevo Therapeutics (APVO) has disclosed Tax Provisions for 4 consecutive years, with -$999000.0 as the latest value for Q3 2019.

  • Quarterly Tax Provisions changed N/A to -$999000.0 in Q3 2019 from the year-ago period, while the trailing twelve-month figure was -$23.5 million through Sep 2019, changed N/A year-over-year, with the annual reading at -$23.3 million for FY2017, 417.57% down from the prior year.
  • Tax Provisions hit -$999000.0 in Q3 2019 for Aptevo Therapeutics, up from -$7.7 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $14.1 million in Q4 2016 to a low of -$17.6 million in Q3 2016.
  • Historically, Tax Provisions has averaged -$2.5 million across 4 years, with a median of -$717500.0 in 2015.
  • Biggest five-year swings in Tax Provisions: skyrocketed 2409.51% in 2016 and later tumbled 8954.55% in 2017.
  • Year by year, Tax Provisions stood at -$610000.0 in 2015, then surged by 2409.51% to $14.1 million in 2016, then plummeted by 154.76% to -$7.7 million in 2017, then soared by 87.05% to -$999000.0 in 2019.
  • Business Quant data shows Tax Provisions for APVO at -$999000.0 in Q3 2019, -$7.7 million in Q4 2017, and -$13.8 million in Q3 2017.